Verrica pharmaceuticals inc. (VRCA)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities
Net loss

-9,822

-

-

-

-7,479

-

-

-

-

Net loss

-

-

-

-

-

-

-

-5,317

-1,847

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

998

802

905

846

780

654

683

779

135

Accretion of discounts on marketable securities

93

183

238

283

359

-

-

-

-

Depreciation expense

14

26

16

11

11

-

-

-

-

Non cash interest expense

65

-

-

-

-

-

-

-

-

Reduction in operating lease right-of-use asset

66

67

67

30

29

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-701

2

1,977

-404

46

-373

261

35

1,000

Other receivable - related party

-

-

-

-

6

-

-

-

-

Accounts payable

-82

174

56

-182

215

-145

341

116

457

Accrued expenses and other current liabilities

279

-

-

-

4

-

-

-

-

Accrued expenses

-

-

-

-

-

171

46

743

108

Accounts payable and accrued expenses - related party

-

-

-

-

-38

-

-

-

-

Accounts payable and accrued expenses - related party

-

-

-

-

-

-

-

29

-7

Operating lease liability

-32

-31

-30

-30

-28

-

-

-

-

Net cash used in operating activities

-7,906

-8,213

-7,228

-5,050

-6,917

-6,903

-5,137

-3,680

-2,154

Cash flows from investing activities
Sales and maturities of marketable securities

24,355

24,500

22,650

28,200

42,365

-

-

-

-

Purchases of marketable securities

5,382

16,623

23,999

27,937

21,295

-

-

-

-

Purchases of property and equipment

699

-

-

-

-

650

13

94

17

Net cash provided by investing activities

18,274

6,650

-2,028

263

21,070

-21,146

-58,637

-94

-17

Cash flows from financing activities
Proceeds from exercise of stock options

7

204

4

212

3

-

-

-

-

Proceeds from issuance of debt, net

34,460

-

-

-

-

-

-

-

-

Repayment of subscription receivable

-410

-

-

-

-

-

-

-

-

Net cash provided by financing activities

34,877

204

4

212

3

9

-1,064

79,438

20,993

Net increase in cash and cash equivalents

45,245

-

-

-

14,156

-

-

-

-

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

75,664

18,822

Supplemental disclosure of noncash investing and financing activities:
Property and equipment purchases payable or accrued at period end

333

-

-93

249

285

-

-

4

2

Debt discount costs included in accrued expense at period end

125

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

472

Series C Convertible Preferred Stock [Member]
Payment of stock issuance costs

-

-

-

-

-

-

-

0

7

Proceeds received from subscription receivable / issuance of preferred stock

-

-

-

-

-

7

-7

0

21,000